<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03714490</url>
  </required_header>
  <id_info>
    <org_study_id>NCC201807007</org_study_id>
    <nct_id>NCT03714490</nct_id>
  </id_info>
  <brief_title>MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer</brief_title>
  <acronym>SUNRISE</acronym>
  <official_title>MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy (SCPRT) Followed by Consolidation Chemotherapy Versus Long Course Chemoradiation for Unresectable Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Improvements in downstaging are required when using preoperative chemoradiation for
      unresectable rectal cancer. There is therefore a need to explore more effective schedules.
      The study arm will receive MRI simulation-guided boost in short-course preoperative
      radiotherapy followed by consolidation chemotherapy , which may enhance the shrinkage of
      tumor comparing with the concurrent chemoradiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective phase II randomized multicenter trial. The purpose of this study
      is to compare short-term radiotherapy with MRI simulation-guided boost followed by
      consolidation chemotherapy(Experimental group) with preoperative long-term
      chemoradiotherapy(Control group) for middle-lower unresectable locally advanced rectal cancer
      evaluated by MRI. The primary endpoint is the rate of R0 resection, and the secondary
      objectives are local recurrence-free survival, distant metastasis-free survival, disease-free
      survival and overall survival at 3-year and 5-year follow up. Furthermore, pathological
      complete response rate, the acute and late toxicity profile and quality of life (QOL) after 3
      years follow-up are secondary endpoints. The exploratory end point includes the circulating
      tumor DNA, and other potential biomarkers from tumor tissue and blood sample for treatment
      response and survival predicting. For each group, a plan for collection of serum/plasma/feces
      at baseline and different stages during or after treatment and for obtaining fresh tumor
      tissue for freezing prior to treatment was defined in the protocol.

      The SUNRISE-trial has been designed by National Cancer Center/Cancer Hospital, Chinese
      Academy of Medical Sciences, Peking Union Medical College, and the hypothesis is R0 resection
      rate in Experimental group was superior to that in Control group.

      Interim analysis design: As a phase II trial, the safety of experimental intervention is a
      major concern. We took the toxicity data from STELLAR, a phase III randomized study led by
      our center, as a reference. The incidence of G3 and above side effects in the short course
      radiotherapy with sequential neoadjuvant chemotherapy group was 28%, and that in the standard
      long-course concurrent chemoradiotherapy control group was 5%. Considering that boost dose
      may increase toxicity, if severe toxicity in the study group significantly exceeds that in
      the control group by more than 35%, it is up to the principal investigator to decide whether
      to modify the study protocol or terminate the study. The sample size of the interim analysis
      was calculated by the Z-pooled test, with α=0.05 (one-sided test), 1-β=0.90, using PASS 11
      software. The frequency of the toxicity of G3 and above should be compared when neoadjuvant
      therapy was completed in 21 patients enrolled in each group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized phase II trial design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0(microscopically margin-negative) resection rate</measure>
    <time_frame>1-month after surgery completed</time_frame>
    <description>the rate of microscopically margin-negative resection after neoadjuvant treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>local recurrence-free survival</measure>
    <time_frame>3-year and 5-year</time_frame>
    <description>the time from surgery to local recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant metastasis-free survival</measure>
    <time_frame>3-year and 5-year</time_frame>
    <description>the time from diagnosis to metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>3-year and 5-year</time_frame>
    <description>the time from surgery to recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3-year and 5-year</time_frame>
    <description>the time from diagnosis to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathological complete response rate</measure>
    <time_frame>1-month after surgery completed</time_frame>
    <description>pathological complete response in surgery specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the acute toxicity profile</measure>
    <time_frame>1-month</time_frame>
    <description>the frequency of acute adverse events during and after treatment in 1-month, including gastrointestinal (vomiting, diarrhea and incontinence), dermatitis, and hematologic toxicity evaluated weekly by the Common Terminology Criteria 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the late toxicity profile</measure>
    <time_frame>3-year</time_frame>
    <description>the late toxicity after treatment completion for 1-month, the frequency of late adverse events after 1-month of treatment, including gastrointestinal function, fistula, and hematologic toxicity, evaluated regularly by LENT-SOMA scoring systems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>general quality of life (QoL) by QLQ-30</measure>
    <time_frame>3-year</time_frame>
    <description>general quality of life of patients evaluated by questionaire of EORTC QLQ-C30. The higher score in total indicates the worse quality of life in general.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL by QLO-CR29</measure>
    <time_frame>3-year</time_frame>
    <description>quality of life related to colorectal disease of patients evaluated by questionaire of EORTC QLQ-CR29. The higher score in total of this module indicates the worse quality of life by colorectal module.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>circulating tumor DNA, and other potential biomarkers such as T-cell receptor</measure>
    <time_frame>3-year</time_frame>
    <description>The exploratory end point for predicting of treatment response and survival. The circulating tumor DNA test by sequencing will includes KRAS, NRAS, BRAF,PI3K,TP53,PTEN, EGFR, NEGF etc (509-gene panel). And Measuring change in T cell receptor sub-types during treatment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Rectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention of Experimental group includes: Radiotherapy, followed by chemotherapy with capecitabine, oxaliplatin, and then surgery. The detail of procedure: 1, short-course preoperative radiotherapy(SCPRT) , which consists of SCPRT, 5 Gray(Gy) x 5, 4Gy for boost on the gross tumour volume(GTV) with MRI-simulation alone; 2,then after 7-10 days of radiotherapy completed, patients will receive consolidation chemotherapy, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are prescribed preoperatively, then followed by a total mesorectal excision(TME) and postoperative adjuvant chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The intervention of Control group includes:Radiotherapy, capecitabine, and surgery. The detail of procedure: 1, long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively; 2, 6-8 weeks after chemoradiation, total mesorectal excision(TME) and then postoperative adjuvant chemotherapy. The radiotherapy is given in combination with capecitabine in a dose of 825 mg/m2 twice daily on days when radiotherapy, excluding weekends.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SCPRT plus neoadjuvant chemotherapy</intervention_name>
    <description>Short-course preoperative radiotherapy(SCPRT) with neoadjuvant chemotherapy, which consists of SCPRT, 5 Gy x 5, 4Gy for boost on the GTV with MRI-simulation alone, then after 7-10 days of radiotherapy completed, patients will receive consolidation chemotherapy, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are scheduled before surgery.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>capecitabine, oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>long course chemoradiation</intervention_name>
    <description>Long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven rectal adenocarcinoma;

          -  Distance between tumour and anal verge≤ 10cm;

          -  Locally advanced tumour;(AJCC Cancer Staging:T3, T4 or N+)

          -  Mesorectal fascia(MRF)+ or T4b evaluated by pelvic MRI;

          -  Eastern Cooperative Oncology Group(ECOG) performance score ≤ 1;

          -  Written informed consent;

          -  Mentally and physically fit for chemotherapy;

          -  Adequate blood counts: White blood cell count ≥3.5 x 109/L Haemoglobin levels ≥100g/L
             Platelet count ≥100 x 109/L Creatinine levels ≤1.0× upper normal limit（UNL） Urea
             nitrogen levels ≤1.0× upper normal limit（UNL） Alanine aminotransferase(ALT) ≤1.5×
             upper normal limit（UNL） Aspartate aminotransferase(AST) ≤1.5× upper normal limit（UNL）
             Alkaline phosphatase(ALP) ≤1.5× upper normal limit（UNL） Total bilirubin(TBIL) ≤1.5×
             upper normal limit（UNL）

          -  No excision of tumor, chemotherapy or other anti-tumor treatment after the diagnosis.

        Exclusion Criteria:

          -  Distant metastases;

          -  Recurrent rectal cancer;

          -  Active Crohn's disease or ulcerative colitis;

          -  Concomitant malignancies;(except basocellular carcinoma or in-situ cervical carcinoma)

          -  Allergic to Fluorouracil or Platinum drugs;

          -  Contraindications to MRI for any reason;

          -  Concurrent uncontrolled medical condition;

          -  Pregnancy or breast feeding;

          -  Known malabsorption syndromes or lack of physical integrity of upper gastrointestinal
             tract;

          -  Symptoms or history of peripheral neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Jin, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Jin, M.D.</last_name>
    <phone>86-010-87788503</phone>
    <email>jinjing@csco.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wen-Yang Liu, M.D.</last_name>
    <phone>13810753633</phone>
    <email>liuwenyang26@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Jin, MD</last_name>
      <phone>+8613601365130</phone>
      <email>jingjin1025@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.</citation>
    <PMID>25651787</PMID>
  </reference>
  <reference>
    <citation>Chen W, Zheng R, Zeng H, Zhang S, He J. Annual report on status of cancer in China, 2011. Chin J Cancer Res. 2015 Feb;27(1):2-12. doi: 10.3978/j.issn.1000-9604.2015.01.06.</citation>
    <PMID>25717220</PMID>
  </reference>
  <reference>
    <citation>Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, Arnold D; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40. doi: 10.1093/annonc/mdx224. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv263. Ann Oncol. 2018 Oct;29 Suppl 4:iv263.</citation>
    <PMID>28881920</PMID>
  </reference>
  <reference>
    <citation>Bujko K, Wyrwicz L, Rutkowski A, Malinowska M, Pietrzak L, Kryński J, Michalski W, Olędzki J, Kuśnierz J, Zając L, Bednarczyk M, Szczepkowski M, Tarnowski W, Kosakowska E, Zwoliński J, Winiarek M, Wiśniowska K, Partycki M, Bęczkowska K, Polkowski W, Styliński R, Wierzbicki R, Bury P, Jankiewicz M, Paprota K, Lewicka M, Ciseł B, Skórzewska M, Mielko J, Bębenek M, Maciejczyk A, Kapturkiewicz B, Dybko A, Hajac Ł, Wojnar A, Leśniak T, Zygulska J, Jantner D, Chudyba E, Zegarski W, Las-Jankowska M, Jankowski M, Kołodziejski L, Radkowski A, Żelazowska-Omiotek U, Czeremszyńska B, Kępka L, Kolb-Sielecki J, Toczko Z, Fedorowicz Z, Dziki A, Danek A, Nawrocki G, Sopyło R, Markiewicz W, Kędzierawski P, Wydmański J; Polish Colorectal Study Group. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016 May;27(5):834-42. doi: 10.1093/annonc/mdw062. Epub 2016 Feb 15.</citation>
    <PMID>26884592</PMID>
  </reference>
  <reference>
    <citation>Braendengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Påhlman L, Wiig JN, Byström P, Bujko K, Glimelius B. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol. 2008 Aug 1;26(22):3687-94. doi: 10.1200/JCO.2007.15.3858.</citation>
    <PMID>18669453</PMID>
  </reference>
  <reference>
    <citation>Burbach JP, den Harder AM, Intven M, van Vulpen M, Verkooijen HM, Reerink O. Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: a systematic review and meta-analysis. Radiother Oncol. 2014 Oct;113(1):1-9. doi: 10.1016/j.radonc.2014.08.035. Epub 2014 Oct 1. Review.</citation>
    <PMID>25281582</PMID>
  </reference>
  <reference>
    <citation>Teo MTW, McParland L, Appelt AL, Sebag-Montefiore D. Phase 2 Neoadjuvant Treatment Intensification Trials in Rectal Cancer: A Systematic Review. Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):146-158. doi: 10.1016/j.ijrobp.2017.09.042. Epub 2017 Sep 29. Review.</citation>
    <PMID>29254769</PMID>
  </reference>
  <reference>
    <citation>Caravatta L, Padula GD, Picardi V, Macchia G, Deodato F, Massaccesi M, Sofo L, Pacelli F, Rotondi F, Cecere G, Sallustio G, Di Lullo L, Piscopo A, Mignogna S, Bonomo P, Cellini N, Valentini V, Morganti AG. Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: results of a phase II study. Acta Oncol. 2011 Nov;50(8):1151-7. doi: 10.3109/0284186X.2011.582880. Epub 2011 Aug 18.</citation>
    <PMID>21851185</PMID>
  </reference>
  <reference>
    <citation>Engels B, Platteaux N, Van den Begin R, Gevaert T, Sermeus A, Storme G, Verellen D, De Ridder M. Preoperative intensity-modulated and image-guided radiotherapy with a simultaneous integrated boost in locally advanced rectal cancer: report on late toxicity and outcome. Radiother Oncol. 2014 Jan;110(1):155-9. doi: 10.1016/j.radonc.2013.10.026. Epub 2013 Nov 12.</citation>
    <PMID>24239243</PMID>
  </reference>
  <reference>
    <citation>Lee JH, Kim DY, Nam TK, Yoon SC, Lee DS, Park JW, Oh JH, Chang HJ, Yoon MS, Jeong JU, Jang HS. Long-term follow-up of preoperative pelvic radiation therapy and concomitant boost irradiation in locally advanced rectal cancer patients: a multi-institutional phase II study (KROG 04-01). Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):955-61. doi: 10.1016/j.ijrobp.2012.01.045. Epub 2012 Apr 24.</citation>
    <PMID>22537540</PMID>
  </reference>
  <reference>
    <citation>Li JL, Ji JF, Cai Y, Li XF, Li YH, Wu H, Xu B, Dou FY, Li ZY, Bu ZD, Wu AW, Tham IW. Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial. Radiother Oncol. 2012 Jan;102(1):4-9. doi: 10.1016/j.radonc.2011.07.030. Epub 2011 Sep 6.</citation>
    <PMID>21903285</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 9, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jing Jin, M.D.</investigator_full_name>
    <investigator_title>Professor, Director of medical services</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>short-term radiotherapy</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>total mesorectal excision</keyword>
  <keyword>MRI-simulation</keyword>
  <keyword>boost</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

